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Abstract  Hairy  cell  leukemia  (HCL)  is  an  uncommon  B-cell  lymphoid  neoplasia,  representing
2--3% of  all  leukemias.  It  is  more  common  in  men,  with  a  median  age  at  diagnosis  of  52  years.
The hair-like  projections  on  its  surface  are  its  principal  characteristic.  Although  its  etiology  has
not been  established,  the  recent  gene  sequencing  of  HCL  identiﬁed  the  presence  of  the  BRAF
V600E mutation,  absent  in  other  malignant  neoplasias  of  the  lymph  cells.  The  clinical  course  of
the disease  is  usually  indolent.  The  majority  of  patients  initially  present  weakness  and  fatigue,
pancytopenia  and  splenomegaly.
HCL must  be  distinguished  from  other  indolent  lymphoid  neoplasias  such  as  prolymphocytic
leukemia,  splenic  marginal  zone  lymphoma,  the  variant  of  HCL  (HCLv),  and  mantle  cell  lym-
phoma. Peripheral  blood  ﬂow  cytometer  is  essential  for  the  detection  of  CD11c,  CD19,  CD20,
CD22, CD25,  and  CD10,  as  well  as  a  bone  marrow  aspirate  to  detect  immunophenotypes.  In  addi-
tion, a  bone  biopsy  is  useful  to  perform  an  immunohistochemistry  analysis  for  TRAP,  DBA-44  and
A1 annexin.
Purine  analogues  remain  the  ﬁrst  line  of  treatment.  However,  interferon  and  rituximab  are
a valid  option,  if  the  ideal  treatment  is  unavailable.  New  discoveries  in  the  pathophysiology
of HCL  have  brought  the  creation  of  pharmaceuticals  with  distinct  therapeutic  targets.  These
pharmaceuticals  are  currently  undergoing  testing.
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airy  cell  leukemia  (HCL)  is  a  B-cell  lymphoid  neoplasia.
CL  differentiates  from  other  B-cell  neoplasms  because  of
ts  morphological,  immunophenotypic  and  molecular  char-
cteristics.  Its  main  characteristic  is  the  accumulation
f  monoclonal  B  cells,  with  hair-like  projections  on  its
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pHCL,  an  uncommon  B-cell  lymphoid  neoplasia  
surface,  mainly  found  in  peripheral  blood,  bone  marrow  and
the  spleen.  It  was  described  in  1958  by  Bournoncle  et  al.
However,  they  called  it  leukemic  reticuloendotheliosis.1 The
term  ‘‘hairy  cells’’  was  coined  in  1996  by  Schrek  et  al.2
Today  it  is  classiﬁed  by  the  World  Health  Organization  as
a  B-cell  non-Hodgkin  lymphoma.3
Deﬁnition
HCL  is  a  rare,  chronic,  lymphoproliferative  B-cells  disorder.
Its  main  characteristics  are  the  cytoplasmic  prolongations
which  give  the  cells  a  hairy  aspect.
Etiology
Although  there  are  different  studies  showing  a  link  between
exposure  to  certain  agents  and  HCL,  its  etiology  has  not  been
clearly  established,  which  could  be  explained  due  to  its  low
incidence.  Amongst  the  agents  which  have  proven  a  positive
link  are:  exposition  to  pesticides,4 herbicides,  mineral  oils,
working  as  a  carpenter,  or  a  farmer.4--7 Recently,  a  positive
link  with  size  has  been  described,5 whereas  smoking  has  an
inverse  association,  especially  in  men.8 The  speciﬁc  mecha-
nism  which  confers  the  protection  is  unknown;  nevertheless,
smoking  has  been  suggested  to  decrease  the  severity  of
inﬂammatory  mechanisms9 and  that  nicotine  induces  apo-
ptosis  in  lymphocytes.10
Epidemiology
HCL  represents  2--3%  of  all  leukemias.  There  are  600  new
cases  reported  per  year  in  the  U.S.  (3.2  cases  per  million
inhabitants).  Median  age  at  diagnosis  is  52  years  old  and  it
is  more  common  in  men  than  in  women,  with  a  4:1  ratio;
with  a  higher  incidence  in  the  white  population,  especially
among  Ashkenazi  Jews.3 In  Mexico,  HCL  represents  1.12%
of  all  leukemias.  However,  in  the  north  of  the  country  it
represents  up  to  1.83%,  similar  to  the  information  from  the
U.S.11,12
Physiopathology
HCL  is  a  chronic,  lymphoproliferative  B-cell  disorder.  How-
ever,  its  cells  do  not  have  the  appearance  of  any  B-cell
sub-population,  and  its  origin  has  been  a  matter  of  debate.
The  analysis  of  immunoglobulins  (Ig)  variable  regions  genes
is  a  tool  used  to  discover  the  lymphoid  cells’  clonal  origin.13
In  over  85%  of  cases,  we  are  able  to  ﬁnd  somatic  mutations
in  Ig  variable  regions  genes  of  HCL  cells,14,15 which  is  an
indication  that  the  cells  involved  have  passed  through  the
germinal  center  or  lymphoid  peripheral  organs.16 Approxi-
mately  40%  of  HCL  cells  co-express  multiple  clonally-related
Ig  isotypes.17
Evidence  suggests  an  origin  post  germinal  center  in  mem-
ory  B-cells,  due  to  their  genomic  expression  proﬁle.18,19 The
origin  of  memory  B-cells  is  compatible  with  HCL’s  lack  of
chromosomic  reciprocal  translocation.20 Absence  of  CD27  is
typical  in  HCL.  This  represents  a  point  against  the  hypothe-
sis  of  its  origin  in  memory  B-cells.21 However,  negative  CD27
memory  B-cells  have  been  observed.22 Since  lymph  node
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ffection  is  infrequent,  it  has  been  suggested  that  the  HCL
rigin  cell  is  probably  located  in  the  bone  marrow  or  spleen,
ince  those  are  usually  the  more  affected  places.  HCL  cells
how  an  expression  proﬁle  similar  to  the  spleen’s  marginal
one.23
HCL’s  characteristic  look  is  due  to  the  beta-actin  expres-
ion,  which  is  polymerized  to  F-actin,  located  in  the  cortical
ytoskeleton.24 PP52  phosphoprotein,  which  is  speciﬁc  for
eukocytes,  is  linked  to  F-actin  and  is  responsible  for  bring-
ng  support  to  the  hair-like  projections.25 On  the  other  hand,
CL  gene  sequencing  recently  identiﬁed  the  presence  of
 BRAF  V600E  mutation  in  almost  every  patient  with  the
isease,  absent  in  other  B-cell  lymphoid  malignancies.26,27
RAF  mutations  activate  the  MAPK  pathway,  promoting
rowth,  survival  and  HCL  cell  differentiation.28
linical presentation and lab ﬁndings
he  disease’s  clinical  course  is  indolent.  Most  patients
sually  present  weakness  and  fatigue  as  the  predominant
ymptoms  during  the  onset  of  the  disease.29 Sometimes,
here  is  a  history  of  repeated  infections.  The  ﬁsical  exam-
nation  ﬁndings  are:  splenomegaly  in  96%,  hepatomegaly  in
8%  and  lymphadenopathy  in  only  35%.  These  swollen  lymph
odes  are  rarely  observed  in  the  periphery;  nonetheless,
hey  are  generally  present  in  the  abdomen  and  detected
y  imaging  studies.30
In  an  advanced  stage  of  the  disease  we  are  able  to
nd  pain  in  the  superior  left  quadrant,  infections,  fever,
nd  hemorrhages  and/or  weight  loss.  However,  this  is
ncommon  because  of  the  availability  and  effectiveness  of
reatment.30,31 Clinical  manifestations  are  product  of  hairy
ell  accumulation  in  the  spleen,  liver  and  bone  marrow
Table  1).32
Respect  to  lab  studies,  it  is  frequent  to  observe  anemia
n  85%,  thrombocytopenia  in  60.80%  and  leukopenia  in  60%
ue  to  hypersplenism  and  bone  marrow  inﬁltration.30
ifferential diagnosis
CL  must  be  differentiated  from  other  indolent  lymphoid
alignancies  such  as  prolymphocytic  leukemia,  splenic
arginal  zone  lymphoma,  mantle  cell  lymphoma  and  HCL
ariant  (HCL-v).  The  last  one  occurs  in  10%  of  cases  with  a
edian  age  of  70  years,  and  despite  the  similarities  with
lassic  hairy  cell  leukemia,  they  diverge  in  the  absence  of
he  CD25  and  CD123  immunophenotypic  markers.  Another
ay  of  making  a  differential  diagnosis  is  the  lack  of  response
o  standard  HCL  treatment  and  the  nonexistence  of  muta-
ions  of  the  BRAF  V600F  gene.30
iagnostic methods
CL  diagnosis  is  commonly  made  with  a  biopsy  and  bone
arrow  aspiration  combined  with  immunophenotypic  char-
cterization  through  ﬂow  cytometry.33 It  is  important  to
oint  out  that  this  pathology  is  usually  sub-diagnosed
nd  requires  clinical  suspicion  and  the  use  of  the  proper
echnology  to  solve  this  problem.  As  previously  men-
ioned,  most  patients  (70--90%)  present  pancytopenia,  with
eucopenia  (<5  ×  109/L),  anemia  (<10  g/dL),  neutropenia
36  M.A.  Garza-Ledezma  et  al.
Diagnosis
Hairy cell leukemia  
Symptomatic patient Asymptomatic patient 
Start treatment with purine
analogues.
- Cladribin
- Pentostatin
Unfavorable circumstances:
- Alpha interferon.
- Rituximab at a low or
normal dosage.
- Splenectomy     
Keep under surveillance
Lab test every 3 months for
the first year, and every 6
months after that.    
Evaluate rituximab 
Complete response 
or 
Partial response
Relapse 
Delayed (>2 years)
-Retreat with purine
analogues or with
rituximab or interferon.
Early (<2 years)
-Confirm the diagnosis
-BRAF-V600E inhibitors
-Inmunotoxins
-Ibrutinib
-Rituximab and interferon.
Algorithm  1  Chart  for  the  management  of  a  patient  with  hairy  cell  leukemia.
Table  1  Clinical  manifestations.
Spleen  Liver  Bone  marrow  Lymph  nodes
The  cells  accumulate  in  the
red pulp  and  atrophy  the
white  pulp.  They  later
form  the  so-called
‘‘pseudo-sinusoids’’
through  the  replacement
of the  endothelial  cells  of
the red  pulp  by  enhanced
vascular  channels,
contributing  to  anemia.
Here,  they  accumulate
in  the  liver  sinusoids  as
well  as  in  the  portal
tract.  There  is  ﬁbrosis  in
the  latter  due  to  the
abundant  hyaluronic
acid,  which  stimulates
the  hairy  cells  to
produce  ﬁbronectin,
with  its  corresponding
ﬁbrosis.
In  this  area,  there  is
extensive  production  of
ﬁbrosis  and  suppression
of hematopoiesis.  The
key factor  is  the
interaction  of  the  hairy
cells  with  the  hyaluronic
acid  of  the  extracellular
matrix,  generating
ﬁbroblastic  growth
factors  (FGF)  and
stimulating  the  malign
cells  to  produce  and
Generally,  absent  of  the
disease.  Lack  of
receptors  for  entry  of
hairy  cells.
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i<1  ×  109/L),  monocytopenia  (<0.1  ×  109/L)  and  thrombocy-
openia  (<100  ×  109/L).  Only  between  10%  and  20%  present
oderate  leukocytosis  (>10  ×  109/L).  HCL  patients  dis-
lay  elevated  IL-2R  (CD25)  serum  levels,  which  correlates
ith  the  disease’s  degree  of  activity.34 Other  tests  which
hould  be  considered  when  making  the  diagnosis  are  serum
mmunoglobulin  levels,  as  well  as  IgVH  gene  and  BRAF
•secrete  ﬁbronectin.
600E  somatic  mutations.32 Some  HCL  histopathologic  and
mmunophenotypic  characteristics  are  the  following:
 Lymphocyte  ﬂow  cytometry  in  peripheral  blood  or  bone
marrow  with  CD19,  CD20,  FMC7,  CD11c,  CD103,  CD25,
HC2,  CD22,  sIg,  CD79a  and  CD123  expressions,  with  four
being  the  main  and  speciﬁc  markers:  CD11c,  CD103,  CD25
HCL,  an  uncommon  B-cell  lymphoid  neoplasia  
Table  2  Criteria  to  begin  treatment.
1.  Symptomatic  splenomegaly
2.  Cytopenia  involving  at  least  one  of  the  following:
-Hemoglobin  <10  g/dL
-Platelets  <100  ×  109/L
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e-Neutrophils  <1  ×  10 /L
3. Severe  infections
and  CD123.34 Commonly  negative  markers  are  CD5,  CD23,
CD10,  CD79b  and  CD27.32
• A  strong  expression  for  CD200  is  characteristic  of  HCL  and
may  be  useful  in  the  diagnosis  of  difﬁcult  cases.34
•  Bone  marrow  aspiration  with  a  needle  may  be  difﬁcult
to  obtain  and  is  frequently  unproductive  or  ‘‘dry’’.  In  a
bone  marrow  biopsy,  we  can  observe  ﬁbrosis,  with  a  cellu-
lar  ‘‘fried-egg’’  look  caused  by  the  wide  spaces  between
nuclei  and  abundant  cytoplasm.  Immunohistochemistry
analyses  for  CD20  and  TRAP  (tartrate  resistant  acid  phos-
phatase),  DBA-4  and  annexin  A1  are  conducted,  which  are
characteristically  positive.32
Andrulis  et  al.  directed  a  study  where  the  efﬁciency  of
the  VE1  antibody  for  BRAF  V600E  detection  was  reported,
along  with  HCL  identiﬁcation  in  other  entities.  Moreover,  a
study  conducted  by  Uppal  et  al.  found  a  sensitivity  of  88%
and  a  speciﬁcity  of  97%  to  detect  this  mutation  with  the
mentioned  antibody.34
Current treatment
HCL  regularly  has  an  indolent  evolution.  Waiting  and  observ-
ing  is  a  good  option  for  asymptomatic  patients,  since  early
treatment  does  not  offer  any  sort  of  beneﬁt  in  the  sur-
vival  rates  of  these  cases.  Anyway,  the  progression  of  the
disease  in  most  patients  will  lead  to  complications  as  a
result  of  cytopenias  and  splenomegaly;  i.e.  anemia,  hem-
orrhages,  recurrent  infections,  etc.  In  general  practice,
treatment  must  be  started  if  any  of  the  criteria  listed  in
Table  2  occur.35 When  the  decision  to  not  start  treatment
8
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Table  3  Studies  on  the  effectiveness  of  pentostatin  in  HCL  cases
Study  Follow-up  Plan  
Rafel  et  al.
(n =  78)
2.6  years  IV  infusion
4 mg/m2/d
Every  2  weeks
Else et  al.
(n  =  185)
10.8  years  IV  infusion
4 mg/m2/d
Every  2  weeks
Ribeiro et  al.
(n  =  49)
3.2  years  IV  infusion
4 mg/m2/d
Every  2  weeks
Maloisel et  al.
(n  =  238)
5.3  years  IV  infusion
4 mg/m2/d
Every  2  weeks
RC: complete response, RP: partial response, RG: global response.37
s  taken,  clinical  and  laboratory  monitoring  should  be  done
or  every  three  months  during  the  ﬁrst  year  and  every
ix  months  thereafter.35 HCL  treatment  is  not  considered
ealing;  but  current  treatment  strategies  are  capable  of
eaching  prolonged  remissions,  thus  increasing  global  sur-
ival  rates  (Algorithm  1).36--39
urine  analogues
n  1960,  ﬁndings  showed  that  30%  of  children  with  severe
ombined  immunodeﬁciency  syndrome  lacked  deaminase
denosine  enzyme  (ADA).40 Furthermore,  they  discovered
hat  the  accumulation  of  the  deoxyadenosine  triphosphate
orm  was  responsible  for  the  decrease  of  lymphocytes.41
eeping  these  observations  in  mind,  medications  capable
f  binding  irreversibly  to  ADA  or  antagonizing  its  action
ere  developed.  After  treatment  with  purine  analogues,
eoxyadenosine  triphosphate  accumulation  results  in  rup-
ure  and  inhibition  of  the  DNA  repair,  which  translates  into
ellular  apoptosis.42
entostatin
lso  known  as  2′-deoxycoformycin  (dcF),  a  product  of  Strep-
omyces  antibioticus  and  ADA  inhibitors,  ﬁrst  introduced  in
980  as  the  ﬁrst  purine  analogues  for  HCL  treatment.  In
able  3,37,39,43,44 speciﬁc  studies  show  response  rates  to  pen-
ostatin.  Intravenous  use  of  pentostatin  at  a  4  mg/m2 ratio
nce  every  two  weeks  until  reaching  complete  response
as  approved  in  the  U.S.  Pentostatin  is  safe  in  patients
ith  creatinine  lightening  >60  mL/min.  However,  a  dosage
eduction  is  necessary  if  this  depuration  is  between  40  and
0  mL/min.32 Patient  hydration  with  1.5  L  of  intravenous
olution  with  every  pentostatin  cycle  is  recommended.30
Global  response  varies  between  88%  and  96%,  while
omplete  response  is  between  44%  and  81%.  Flinn  et  al.
stimated  a  survival  rate  of  5  and  10  years  of  90%  and
1%,  respectively,  with  a  mean  follow-up  duration  of  9.3
ears.45 Pentostatin  is  generally  well-tolerated  and  the  most
ommon  adverse  effects  are  anemia,  thrombocytopenia
nd  neutropenia.46 Still,  pentostatin  has  been  reported  to
.
%  CR  %  PR  %  GR  Outcome
72  16  88  Event-free  survival:
46  months
81  15  96  Global  survival  at  10
years:  98%
44  52  96  Global  survival:  86%
79  17  96  Global  survival  at  5
years:  88.1%
Global  survival  at  10
years:  68.8%
38  M.A.  Garza-Ledezma  et  al.
Table  4  Studies  on  the  effectiveness  of  cladribine  in  HCL  cases.
Study  Patients  Follow-up  Plan  %  CR  %  PR  %  GR  Outcome
Robak  (1999)  97  36  months  2  h  infusion
IV  0.12  mg/kg/d
5  days
77.3  18.6  95.9  Progression-free
survival:  37.4  months
Rosenberg (2014)  83  NA  Continuous  infusion
IV 0.1  mg/kg/d
7  days
88  12  100  Average  global  survival:
231  months
Goodman (2003)  207  7  years  Continuous  infusion
IV 0.1  mg/kg/d
7  days
95  5  100  Global  survival  at  108
months:  97%
Chadha (2005) 86  9.7  years Continuous  infusion
IV 0.1  mg/kg/d
7  days
79  21  100  Global  survival  at  12
years:  87%
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rRC: complete response, RP: partial response, RG: global response
ecline  CD4+  and  CD8+  lymphocyte  counts  signiﬁcantly,
hich  could  increase  secondary  malignancies  and  incidence
f  infections.47,48
ladribine
t  is  known  as  2-chlorodeoxyadenosine  (CdA).  In  Table  4,49--52
tudies  indicate  its  effectiveness.  The  most  used  scheme
onsists  of  administering  0.1  mg/kg/day  in  a  continuous
nfusion  for  7  days.  In  a  non-randomized  study,  there  was
vidence  proving  that  there  was  no  statistically  signiﬁcant
ifference  in  the  response  and  toxicity  ranges  between
nfusions  (24  h  and  2  h).53 Another  randomized  study  com-
ared  daily  versus  weekly  cladribine  administration;  there
ere  no  signiﬁcant  ﬁndings  in  response,  survival,  global  and
oxicity  rates.54 A  different  study  showed  that  the  weekly
rogram  reduced  the  risk  of  infections.55 One  of  the  advan-
ages  of  subcutaneous  administration  is  the  fact  that  in  most
ases  it  does  not  require  hospitalization.  0.14  mg/day  for  5
ays  has  a  95%  response  rate,56 similar  to  the  intravenous
dministration.  Weekly  subcutaneous  programs  have  simi-
ar  response  and  toxicity  rates  as  daily  ones.57 With  just
ne  cladribine  cycle,  a  global  response  up  to  100%  can
e  obtained,  and  total  response  rates  differ  from  77%  to
5%.49--52 Jehn  et  al.  reported  a  global  survival  at  12  years  of
9%.36 In  general,  cladribine  is  well-tolerated,  with  cytope-
ias  and  fever  being  the  most  common  adverse  effects.
Until  now,  there  are  no  randomized  prospective  studies
omparing  pentostatin  versus  cladribine,  in  part  because
f  the  great  efﬁciency  of  both  drugs  and  due  to  low  HCL
ncidence.  Even  so,  there  are  retrospective  studies  proving
he  fact  that  both  drugs  have  a  similar  efﬁcacy,  in  terms  of
omplete  response  and  free-of-disease  survival.
ther treatments
urine  analogues  remain  the  ﬁrst  line  of  treatment  but  new
iscoveries  regarding  HCL  pathophysiology  have  led  to  the
reation  of  drugs  with  different  therapeutic  targets.  These
rugs  are  under  research  and  some  have  shown  promising
esults.
w
e
tituximab
ince  HCL  is  a  B-cell  malignancy,  it  is  logical  to  use  a  mono-
lonal  antibody  against  CD20,  such  as  rituximab.  Employed
s  a  stand-alone  drug,  rituximab  may  reach  total  response
ates  of  10--54%  in  patients  with  an  HCL  relapse,  at  a
75  mg/m2 dosage  once  a  week  for  4--8  weeks.58,59 Else  et  al.
etrospectively  reviewed  18  patients  who  were  treated  with
urine  analogues  in  combination  with  rituximab  as  a  second
ine  of  treatment,  after  being  treated  with  purine  analogues
s  single  agents.  All  patients  responded,  with  a  complete
esponse  rate  of  89%.60
Rituximab  at  375  mg/m2 per  week  for  8  weeks  as  initial
herapy  after  administrating  5.6  mg/m2 cladribine  via  2-h  IV
nfusion  for  5  days  generates  a  total  response  of  100%.61 In
pecial  or  unfavorable  situations,  100  mg  of  rituximab  per
eek  may  be  utilized  for  4--6  weeks.  This  is  less  expensive
nd  is  usually  effective,  especially  when  is  combined  with
nterferon.
While  purine  analogues  may  not  be  capable  of  elimi-
ating  HCL,  since  minimal  residual  disease  (MRD)  detected
fter  cladribine  administration  is  always  strongly  CD20+,
RD  eradication  may  be  obtained  using  rituximab.  Rivandi
t  al.  proved  in  a  preliminary  study  that  rituximab  at  con-
entional  doses  for  a  period  of  8  weeks  performs  with  great
ctivity,  eliminating  MRD  in  13  patients,  when  it  is  used  4
eeks  after  the  administration  of  cladribine.62
emurafenib
s  described  earlier,  BRAF  V600E  mutation  is  the  genetic
ey  in  HCL.  Therefore,  it  is  a  therapeutic  target  which  has
een  studied  in  recent  years.  Vemurafenib  is  a  BRAF  V600E
ral  inhibitor.  Tiacci  et  al.  conducted  a  study  to  measure
emurafenib  activity  and  safety  in  patients  with  HLC  who
elapsed  after  treatment  with  purine  analogues  or  who  were
efractory  to  the  administration  of  purine  analogues.  Global
esponse  rate  was  96%  and  complete  response  rate  was  35%,
ith  a  relapse-free  survival  mean  of  19  months.  The  adverse
ffects  were  rash,  arthralgia  and  arthritis.63
Since  a  positive  relation  has  been  observed  between
he  use  of  Vemurafenib  and  the  onset  of  dermatological
c
I
q
w
o
r
t
f
o
c
e
c
I
s
m
t
s
a
p
a
p
7
r
ﬁ
s
f
P
S
a
c
a
a
a
w
r
i
w
a
s
D
f
t
f
t
p
C
T
RHCL,  an  uncommon  B-cell  lymphoid  neoplasia  
malignancies,  frequent  explorations  of  the  skin  are  recom-
mended.
Ibrutinib
A  selective  and  irreversible  inhibitor  of  the  Burton’s  tyrosine
kinase  intervenes  in  the  B-cell  signaling  pathway.64 An  ibru-
tinib  clinical  assay  in  patients  with  HCL  relapse  has  recently
begun.  Preliminary  efﬁcacy  and  safety  data  show  adverse
effects  such  as  eruptions,  diarrhea  and  arthralgia.  This  clin-
ical  assay  is  currently  taking  place  in  several  centers  in  the
U.S.  (NCT01841723).
Immunotoxins
In  order  to  increase  monoclonal  antibody  cytotoxicity,  tech-
niques  that  facilitate  the  production  of  antibody--toxin
or  antibody--drug  conjugates  have  been  created.  An
immunotoxin  is  the  fusion  between  a  bacterial  toxin  (i.e.
Pseudomonas  exotoxin  or  diphtheria)  and  the  variable  frac-
tion  of  a  monoclonal  antibody,  whose  speciﬁc  target  is  found
on  the  surface  of  neoplastic  cells  like  CD25  or  CD22.  This
toxin  is  released  in  the  neoplastic  cell’s  interior  and  inter-
feres  with  protein  synthesis.65
BL22  is  an  immunotoxin  against  CD22  fused  with  a  trun-
cated  shape  of  the  P.  exotoxin  PE38.  In  a  phase  II  clinical
assay,  BL22  was  tested  in  36  HCL  relapse  or  refractory
disease  cases.  After  a  cycle  (40  mg/kg  every  two  days,
three  doses),  complete  response  rate  was  25%  and  global
response  rate  was  50%.  These  responses  improved  to  a  total
response  rate  of  47%  and  a  global  response  rate  of  72%
after  retreatment  (only  in  patients  with  cytopenias).  Two
patients  developed  uremic  hemolytic  syndrome  without  the
need  to  recur  to  plasmapheresis.66 Subsequently,  moxetu-
momab  pasudotox  was  developed  as  a  modiﬁed  version  of
BL22  with  a  higher  afﬁnity  and  cytotoxicity.  In  a  phase  I
assay,  which  included  28  patients  with  HCL  relapse  and  resis-
tance,  a  global  response  rate  of  86%  was  obtained,  including
a  sustained  complete  response  rate  in  46%  of  patients.67
Therapeutic options in unfavorable
circumstances
Even  though  HCL  is  treated  in  most  developed  countries  with
cladribine  and  pentostatin,  it  is  a  fact  that  these  drugs  are
not  only  expensive,  they  are  not  available  in  Mexico  and  in
many  countries  with  limited  resources.  So,  in  these  types
of  circumstances,  there  are  other  affordable  therapeutic
options  with  favorable  results
Interferon  alpha  for  HCL  patient  treatment  was  ﬁrst
introduced  in  1984.  Today,  its  use  is  limited,  mainly  due  to
purine  analogues’  great  effectiveness.  On  the  other  hand,
in  countries  with  low  economic  resources,  it  is  an  inex-
pensive  option  and  one  which  has  proved  similar  results  to
those  of  cladribine  in  terms  of  global  survival.  Ruiz-Delgado
et  al.  conducted  a  comparative  study  between  interferon
alpha  (n  =  18)  and  cladribine  (n  =  11),  where  the  difference
in  global  survival  between  both  groups  was  not  statistically
signiﬁcant;  94%  at  217  months  in  the  interferon  group  and
91%  at  133  months  in  the  cladribine  group.68 In  a  study39
onducted  in  our  center,  nine  HCL  patients  received  three
FN  mega-units  three  times  a  week  for  12  weeks,  subse-
uently  they  received  treatment  once  again  for  8  weeks
hen  there  was  a  leukemia  reactivation  or  after  10  months
f  observation  each  year.  All  patients  had  a  hematological
emission  before  12  weeks  of  treatment.  This  therapeu-
ic  option  is  cheaper,  effective  and  comparable  to  other
orms  of  therapy  with  IFN  in  the  treatment  and  maintenance
f  patients  with  this  type  of  leukemia.69 It  is  possible  to
ombine  interferon  with  rituximab  without  increasing  toxic
ffects  and  improving  effectiveness.
Splenectomy  was  the  ﬁrst  intervention  that  signiﬁcantly
hanged  the  survival  in  patients.  Today,  it  is  rarely  used.
t  may  be  recommended  in  patients  with  painful  massive
plenomegaly  (>10  cm  under  the  costal  edge)  and  with  mini-
al  inﬁltration  of  the  bone  marrow,  or  in  patients  refractory
o  treatment  with  interferon  and  purine  analogues.33 Retro-
pective  studies  show  a  complete  response  rate  of  40--62%,
nd  a  mean  survival  rate  at  5  years  up  to  68%.70,71 Lad  et  al.
ublished  a  retrospective  study,  including  24  patients  with
n  HCL  diagnosis,  they  were  divided  into  two  groups:  17
atients  received  cladribine  and  7  were  splenectomized.
5%  of  patients  in  the  splenectomy  group  showed  total
emission,  94%  did  so  in  the  cladribine  group.  An  interesting
nding  when  comparing  both  groups  was  that  no  statistically
igniﬁcant  differences  were  observed  regarding  leukemia-
ree  survival  and  global  survival.72
rognosis
urvival  time  in  patients  after  diagnosis  was  4  years  before
 treatment  was  known,  due  to  complications  derived  from
ytopenias,  including  hemorrhages  and  infections.  There-
fter,  with  splenectomy  as  a  ﬁrst  line  treatment,  there  was
 complete  response  of  40--62%  and  a  survival  rate  of  5  years
t  61--68%.  Then,  alfa  interferon  was  utilized  as  the  ﬁrst  drug
ith  beneﬁts  in  the  treatment  of  HCL.  Still  its  full  response
ate  was  low,  at  10%.73
Today,  with  purine  analogues  (pentostatin  and  cladrib-
ne),  complete  response  is  induced  up  to  80%  of  patients
ith  a  median  survival  of  10  years.  Global  response  rates
re  96--100%  with  a  complete  response  rate  of  80%  and  a
urvival  rate  of  10  years  ranging  between  85%  and  100%.74
espite  that,  a  signiﬁcant  proportion  of  patients  with  HCL
ail  in  their  response  to  treatment  or  become  resistant.  Up
o  48%  of  patients  relapse  in  the  following  15  years.75 The
uture  of  HCL  patients  is  very  favorable.  The  challenge  is
o  identify  this  malignancy  as  early  as  possible  and  treat  it
roperly  using  available  resources.
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